Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
George R. Painter, Michael G. Natchus, Oren J. Cohen, et al.
Current Opinion in Virology (2021) Vol. 50, pp. 17-22
Open Access | Times Cited: 157

Showing 51-75 of 157 citing articles:

Identification of a short ACE2-derived stapled peptide targeting the SARS-CoV-2 spike protein
Lorenzo Calugi, Giulia Sautariello, Elena Lenci, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115118-115118
Open Access | Times Cited: 10
Drug-Repurposing Screening Identifies a Gallic Acid Binding Site on SARS-CoV-2 Non-structural Protein 7
Yushu Gu, Miaomiao Liu, Bart L. Staker, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 4, pp. 578-586
Open Access | Times Cited: 10
An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead
Mehdi Valipour, Hamid Irannejad, Hossein Keyvani
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1248-1265
Open Access | Times Cited: 9
Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach
Yue Yat Harrison Cheung, Eric H. Y. Lau, Guosheng Yin, et al.
International Journal of Infectious Diseases (2024) Vol. 143, pp. 107012-107012
Open Access | Times Cited: 3
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo
Yuexiang Li, Miao Liu, Yunzheng Yan, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1142-1142
Open Access | Times Cited: 15
Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges
Stephen Hanney, Sharon E. Straus, Bev Holmes
Health Research Policy and Systems (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 15
The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)
Pasquale Pagliano, Carmine Sellitto, Tiziana Ascione, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 12, pp. 1299-1311
Closed Access | Times Cited: 15
Host and Viral Zinc-Finger Proteins in COVID-19
Sabrina Esposito, Gianluca D’Abrosca, Anna Antolak, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3711-3711
Open Access | Times Cited: 14
C-2 Thiophenyl Tryptophan Trimers Inhibit Cellular Entry of SARS-CoV-2 through Interaction with the Viral Spike (S) Protein
Marta Gargantilla, Clara Francés‐Gómez, Anmol Adhav, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10432-10457
Open Access | Times Cited: 8
Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment
John Maringa Githaka
Bioinformatics and Biology Insights (2022) Vol. 16, pp. 117793222210850-117793222210850
Open Access | Times Cited: 13
Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
Greta Santi Laurini, Nicola Montanaro, Domenico Motola
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 34-34
Open Access | Times Cited: 13
Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop
Eloise Williams, Kathrine Craig, Christopher Chiu, et al.
Vaccine (2022) Vol. 40, Iss. 26, pp. 3484-3489
Open Access | Times Cited: 12
The Combination of Molnupiravir with Nirmatrelvir or GC376 has a Synergic role in the Inhibition of SARS-CoV-2 Replication in Vitro
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
(2022)
Open Access | Times Cited: 12
The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir)
Ali Adel Dawood
Advances in Medical Sciences (2022) Vol. 68, Iss. 1, pp. 1-9
Open Access | Times Cited: 12
Targeting intracellular Neu1 for coronavirus infection treatment
Darong Yang, Yin Wu, Isaac Turan, et al.
iScience (2023) Vol. 26, Iss. 2, pp. 106037-106037
Open Access | Times Cited: 7
In silico antiviral properties of Spirulina platensis phycobiliprotein and phycobilin as natural inhibitor for SARS-CoV-2
Heli Siti Halimatul Munawaroh, Gun Gun Gumilar, Riska Nur Pratiwi, et al.
Algal Research (2024) Vol. 79, pp. 103468-103468
Closed Access | Times Cited: 2
Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections
Selwyn J. Hurwitz, Ramyani De, Julia C. LeCher, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 651-651
Open Access | Times Cited: 2
Development of a multi-enzyme cascade for 2′3′-cGAMP synthesis from nucleosides
Martin Becker, I. Nowak, Katharina Hildebrand, et al.
Catalysis Science & Technology (2024) Vol. 14, Iss. 12, pp. 3335-3345
Open Access | Times Cited: 2
The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
Thuc Nguyen Dan, Rana Abdelnabi, Bernadett Boda, et al.
Antiviral Research (2024) Vol. 231, pp. 105994-105994
Open Access | Times Cited: 2
Genotoxicity assessment of potentially mutagenic nucleoside analogues using ToxTracker®
Inger Brandsma, Remco Derr, Gaonan Zhang, et al.
Toxicology Letters (2022) Vol. 362, pp. 50-58
Closed Access | Times Cited: 11
Use of Antiviral Agents and other Therapies for COVID-19
Mark A. T. Blaskovich, Anthony D. Verderosa
Seminars in Respiratory and Critical Care Medicine (2023) Vol. 44, Iss. 01, pp. 118-129
Closed Access | Times Cited: 6
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332)
Sven Ullrich, Kasuni B. Ekanayake, Gottfried Otting, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 14
Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
Kritika Srinivasan Rajsri, Mana Rao
Therapeutic Advances in Infectious Disease (2021) Vol. 8
Open Access | Times Cited: 14
Peptidomimetic Small-Molecule Inhibitors of 3CLPro Activity and Spike–ACE2 Interaction: Toward Dual-Action Molecules against Coronavirus Infections
Filomena Tedesco, Lorenzo Calugi, Elena Lenci, et al.
The Journal of Organic Chemistry (2022) Vol. 87, Iss. 18, pp. 12041-12051
Open Access | Times Cited: 10
Advances in the Development of Small Molecule Antivirals against Equine Encephalitic Viruses
Tyler J. Ogorek, Jennifer E. Golden
Viruses (2023) Vol. 15, Iss. 2, pp. 413-413
Open Access | Times Cited: 5

Scroll to top